Mayinglong Pharmaceutical Group Co Ltd (600993) — Cash Flow Reinvestment Rate
Mayinglong Pharmaceutical Group Co Ltd (600993) has a Cash Flow Reinvestment Rate of 0.10x as of September 2025, reinvesting CN¥13.73 Million (capex CN¥13.73 Million ) from operating cash flow of CN¥139.20 Million. See cash generation quality of Mayinglong Pharmaceutical Group Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Mayinglong Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate (2003–2025)
Historical reinvestment intensity for Mayinglong Pharmaceutical Group Co Ltd across 22 annual periods. For the full cash flow conversion analysis, see 600993 cash flow conversion.
Annual Cash Flow Reinvestment Rate for Mayinglong Pharmaceutical Group Co Ltd (2003–2025)
Year-by-year capital reinvestment analysis for Mayinglong Pharmaceutical Group Co Ltd. See 600993 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.44x | CN¥862.67 Million | CN¥600.44 Million | CN¥119.37 Million | ▲ +170.2% |
| 2024 | 0.53x | CN¥264.57 Million | CN¥497.61 Million | CN¥203.85 Million | ▼ -53.9% |
| 2023 | 1.15x | CN¥696.64 Million | CN¥604.07 Million | CN¥248.36 Million | ▼ -43.2% |
| 2022 | 2.03x | CN¥693.77 Million | CN¥341.85 Million | CN¥75.01 Million | ▲ +1091.8% |
| 2021 | 0.17x | CN¥101.69 Million | CN¥597.17 Million | CN¥65.10 Million | ▼ -86.8% |
| 2020 | 1.29x | CN¥365.76 Million | CN¥282.99 Million | CN¥45.41 Million | ▲ +746.3% |
| 2019 | 0.15x | CN¥75.07 Million | CN¥491.58 Million | CN¥46.36 Million | ▼ -28.2% |
| 2018 | 0.21x | CN¥65.52 Million | CN¥308.24 Million | CN¥24.96 Million | ▼ -43.1% |
| 2017 | 0.37x | CN¥133.13 Million | CN¥356.17 Million | CN¥41.91 Million | ▼ -74.6% |
| 2016 | 1.47x | CN¥352.23 Million | CN¥239.60 Million | CN¥65.24 Million | ▼ -5.7% |
| 2015 | 1.56x | CN¥285.18 Million | CN¥182.85 Million | CN¥123.93 Million | ▲ +63.0% |
| 2014 | 0.96x | CN¥106.87 Million | CN¥111.67 Million | CN¥106.87 Million | ▲ +48.6% |
| 2013 | 0.64x | CN¥83.68 Million | CN¥129.94 Million | CN¥83.68 Million | ▲ +232.8% |
| 2012 | 0.19x | CN¥32.75 Million | CN¥169.25 Million | CN¥32.75 Million | ▼ -67.4% |
| 2011 | 0.59x | CN¥44.69 Million | CN¥75.37 Million | CN¥44.69 Million | ▲ +266.9% |
| 2009 | 0.16x | CN¥34.93 Million | CN¥216.11 Million | CN¥34.93 Million | ▼ -49.5% |
| 2008 | 0.32x | CN¥32.84 Million | CN¥102.59 Million | CN¥32.84 Million | ▼ -91.6% |
| 2007 | 3.80x | CN¥24.65 Million | CN¥6.49 Million | CN¥24.65 Million | ▲ +1242.0% |
| 2006 | 0.28x | CN¥21.32 Million | CN¥75.27 Million | CN¥21.32 Million | ▼ -54.0% |
| 2005 | 0.62x | CN¥35.95 Million | CN¥58.43 Million | CN¥35.95 Million | ▲ +15.2% |
| 2004 | 0.53x | CN¥28.94 Million | CN¥54.19 Million | CN¥28.94 Million | ▲ +148.1% |
| 2003 | 0.22x | CN¥14.54 Million | CN¥67.52 Million | CN¥14.54 Million | — |